Efficacy of neoadjuvant tamoxifen therapy on ER/PR Positive and HER2 negative breast cancer patient
Marc Denver S Yray
Vicente Sotto Medical, Philippines
: J Clin Exp Oncol
This is an Analytical Cross sectional Retrospective study to be done in Vicente Sotto Memorial Medical Center reviewing the tumor regression in all breast cancer patients with Estrogen Receptor positive and HER2 negative that were given Tamoxifen as Neoadjuvant Hormonal therapy form a time period of April 1 2016 to April 1 2017. Administration of once daily for a minimum of 5 months can result to greater than 50% regression, thereby making it an effective regimen comparable to neoadjuvant chemotherapy in managing ER +, HER2 – breast cancer patients.
E-mail: [email protected]